VERESCA FOXC1 Prognostic and Predictive Data in Oral Cancer Presented at Nature Conference 2024

SAN DIEGO - June 10, 2024 - PRLog -- Onconostic Technologies-3N Diagnostics Group (OT/3NDx), an emerging leader in precision oncology diagnostics, today announced clinical validation of the pan-cancer, tissue agnostic utility of VERESCA based on detection of FOXC1 protein in oral cancer. The data was presented at the 2024 Nature Conference Cancer Immunotherapy: From Bench to Bedside and Back held on June 10 - 12, 2024 at Joseph B. Martin Conference Center, Boston, MA.

"The results demonstrated that FOXC1 protein detected by immunohistochemistry (IHC) using the VERESCA test can predict efficacy of adjuvant chemoradiation therapy in Oral Squamous Cell Carcinoma (OSCC) patients as well as predict their subsequent prognosis," stated Geetashree Mukherjee, MD, Senior Consultant & Head, Histopathology TMC, Kolkata and presenting author on the study. "We also presented data on how the same marker approach can predict which patients may benefit from receiving neoadjuvant immunotherapy."

"OSCC currently has limited treatment options and is associated with poor prognosis. This data is highly promising, and we look forward to further validation in larger datasets," said Roberto Fagnani, PhD, President and COO of OT/3NDx. "This is a critical milestone as it demonstrates the first clinical validation of VERESCA, our pan-cancer, tissue agnostic test, outside of breast cancer."

About VERESCA FOXC1 IHC Precision Oncology Test

OT/3NDx's patented VERESCA FOXC1 IHC test identifies tumor biopsy FOXC1 expression levels to guide personalized treatment selection for hormonal therapy, chemotherapy, and immunotherapy. It is the only pan-cancer, tissue-agnostic test to identify those patients who are at heightened risk of suffering metastatic recurrence and helps to identify those who are most likely to benefit from life-saving chemotherapy and targeted therapies. VERESCA has been validated in over 17,000 cancer patients. The test is CE Marked and commercially available to hospitals and oncologists in the European Union and countries recognizing CE Marking.

About OT/3NDx

OT/3NDx is leading precision oncology diagnostics with its versatile VERESCA FOXC1 test. We are dedicated to personalizing cancer diagnostics and therapy for patients, physicians and drug developers worldwide. Our CE Marked test enables multidisciplinary medical teams to identify previously unidentifiable aggressive cancers, personalize treatment selection, and identify which patients will benefit from targeted drug therapies.

For more information on OT/3NDx, please visit: www.onconostic.com or www.3ndx.com and follow us on LinkedIn.